Free Trial

Pulse Biosciences (NASDAQ:PLSE) Posts Quarterly Earnings Results, Misses Expectations By $0.03 EPS

Pulse Biosciences logo with Medical background
Remove Ads

Pulse Biosciences (NASDAQ:PLSE - Get Free Report) posted its quarterly earnings data on Thursday. The company reported ($0.27) earnings per share for the quarter, missing analysts' consensus estimates of ($0.24) by ($0.03), Zacks reports.

Pulse Biosciences Stock Down 3.1 %

Pulse Biosciences stock traded down $0.51 during mid-day trading on Monday, hitting $16.09. 459,987 shares of the stock were exchanged, compared to its average volume of 198,258. Pulse Biosciences has a 12 month low of $6.60 and a 12 month high of $25.00. The firm's fifty day simple moving average is $18.78 and its two-hundred day simple moving average is $18.15.

Analyst Ratings Changes

Separately, StockNews.com upgraded Pulse Biosciences to a "sell" rating in a research report on Monday.

Read Our Latest Report on Pulse Biosciences

About Pulse Biosciences

(Get Free Report)

Pulse Biosciences, Inc operates as a novel bioelectric medicine company. The company offers CellFX System, a tunable, software-enabled, and console-based platform that delivers nano second duration pulses of electrical energy to non-thermally clear targeted cells while sparing adjacent non-cellular tissue to treat a various medical condition by using its Nano-Pulse Stimulation technology.

See Also

Earnings History for Pulse Biosciences (NASDAQ:PLSE)

Should You Invest $1,000 in Pulse Biosciences Right Now?

Before you consider Pulse Biosciences, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Pulse Biosciences wasn't on the list.

While Pulse Biosciences currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

13 Stocks Institutional Investors Won't Stop Buying Cover

Which stocks are hedge funds and endowments buying in today's market? Enter your email address and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying now.

Get This Free Report
Like this article? Share it with a colleague.
Remove Ads

Featured Articles and Offers

Recent Videos

Trump Tariffs Tumble the Stock Market—Here’s How to Protect Your Money
Donald Trump Owns These 7 Stocks, Should You?
 5 Stocks to BUY NOW in April 2025

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines

Remove Ads